4 reports of this reaction
2.8% of all ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY reports
#3 most reported adverse reaction
APPLICATION SITE RASH is the #3 most commonly reported adverse reaction for ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY, manufactured by The Procter & Gamble Manufacturing Company. There are 4 FDA adverse event reports linking ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY to APPLICATION SITE RASH. This represents approximately 2.8% of all 144 adverse event reports for this drug.
Patients taking ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY who experience application site rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE RASH is a less commonly reported adverse event for ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY, but still significant enough to appear in the safety profile.
In addition to application site rash, the following adverse reactions have been reported for ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY:
The following drugs have also been linked to application site rash in FDA adverse event reports:
APPLICATION SITE RASH has been reported as an adverse event in 4 FDA reports for ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE RASH accounts for approximately 2.8% of all adverse event reports for ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY, making it one of the most commonly reported side effect.
If you experience application site rash while taking ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.